WO2011153224A3 - Diagnostic methods and compositions for treatment of cancer - Google Patents

Diagnostic methods and compositions for treatment of cancer Download PDF

Info

Publication number
WO2011153224A3
WO2011153224A3 PCT/US2011/038739 US2011038739W WO2011153224A3 WO 2011153224 A3 WO2011153224 A3 WO 2011153224A3 US 2011038739 W US2011038739 W US 2011038739W WO 2011153224 A3 WO2011153224 A3 WO 2011153224A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
treatment
compositions
diagnostic methods
methods
Prior art date
Application number
PCT/US2011/038739
Other languages
French (fr)
Other versions
WO2011153224A2 (en
Inventor
Priti Hegde
Daniel S. Chen
Maike Schmidt
Original Assignee
Genentech, Inc.
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc., F. Hoffmann-La Roche Ag filed Critical Genentech, Inc.
Publication of WO2011153224A2 publication Critical patent/WO2011153224A2/en
Publication of WO2011153224A3 publication Critical patent/WO2011153224A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

Disclosed herein are methods and compositions useful for the diagnosis and treatment of cancer, including, e.g., melanoma.
PCT/US2011/038739 2010-06-02 2011-06-01 Diagnostic methods and compositions for treatment of cancer WO2011153224A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35087210P 2010-06-02 2010-06-02
US61/350,872 2010-06-02

Publications (2)

Publication Number Publication Date
WO2011153224A2 WO2011153224A2 (en) 2011-12-08
WO2011153224A3 true WO2011153224A3 (en) 2012-05-31

Family

ID=44627036

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/038739 WO2011153224A2 (en) 2010-06-02 2011-06-01 Diagnostic methods and compositions for treatment of cancer

Country Status (1)

Country Link
WO (1) WO2011153224A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10460831B2 (en) 2012-12-03 2019-10-29 Koninklijke Philips N.V. Predictive outcome assessment for chemotherapy with neoadjuvant bevacizumab

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010003057A2 (en) * 2008-07-03 2010-01-07 Mayo Foundation For Medical Education And Research Treating cancer
WO2010006232A1 (en) * 2008-07-11 2010-01-14 Genentech, Inc. Methods and compositions for diagnostic use for tumor treatment
WO2011008696A2 (en) * 2009-07-13 2011-01-20 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
WO2011107939A1 (en) * 2010-03-01 2011-09-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of predicting efficacy of an anti-vegfa treatment for solid tumors

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (en) 1990-01-12 1996-12-12 Cell Genesys Inc GENERATION OF XENOGENIC ANTIBODIES
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (en) 1990-08-29 2006-02-16 Genpharm International, Inc. TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES.
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2206447T3 (en) 1991-06-14 2004-05-16 Genentech, Inc. HUMANIZED ANTIBODY FOR HEREGULINE.
CA2145985C (en) 1992-10-28 2003-09-16 Napoleone Ferrara Vascular endothelial cell growth factor antagonists
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
ES2304786T3 (en) 1995-04-27 2008-10-16 Amgen Fremont Inc. ANTI-IL-8 HUMAN ANTIBODIES, DERIVED FROM IMMUNIZED XENORATONES.
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc Human antibodies derived from immunized xenomice
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
JP4464466B2 (en) 1996-03-05 2010-05-19 アストラゼネカ・ユーケイ・リミテッド 4-anilinoquinazoline derivatives
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
TR199900048T2 (en) 1996-07-13 1999-04-21 Glaxo Group Limited Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
DK1500329T3 (en) 1996-12-03 2012-07-09 Amgen Fremont Inc Human antibodies that specifically bind TNF-alpha
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
EP3260468A1 (en) 1997-04-07 2017-12-27 Genentech, Inc. Anti-vegf antibodies
EP0973804B1 (en) 1997-04-07 2006-12-27 Genentech, Inc. Anti-vegf antibodies
CA2289102A1 (en) 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
JP2002501532A (en) 1997-05-30 2002-01-15 メルク エンド カンパニー インコーポレーテッド Novel angiogenesis inhibitors
ATE368665T1 (en) 1997-08-22 2007-08-15 Astrazeneca Ab OXINDOLYLQUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS
EP1017682A4 (en) 1997-09-26 2000-11-08 Merck & Co Inc Novel angiogenesis inhibitors
CN1280580A (en) 1997-11-11 2001-01-17 辉瑞产品公司 Thienopyrimidine and thienopyridine derivatives useful as anti-cancer agents
ATE531812T1 (en) 1997-12-05 2011-11-15 Scripps Research Inst HUMANIZATION OF RODENT ANTIBODIES
ATE375365T1 (en) 1998-04-02 2007-10-15 Genentech Inc ANTIBODIES VARIANTS AND FRAGMENTS THEREOF
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
HUP0103617A2 (en) 1998-05-29 2002-02-28 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors, pharmaceutical compositions containing the compounds and their use
UA60365C2 (en) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Isothiazole derivatives, a method for preparing thereof, a pharmaceutical composition and a method for treatment of hyperproliferative disease of mammal
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
EP1276702A2 (en) 2000-03-31 2003-01-22 Genentech, Inc. Compositions and methods for detecting and quantifying gene expression
AR042586A1 (en) 2001-02-15 2005-06-29 Sugen Inc 3- (4-AMIDOPIRROL-2-ILMETILIDEN) -2-INDOLINONE AS INHIBITORS OF PROTEIN KINASE; YOUR PHARMACEUTICAL COMPOSITIONS; A METHOD FOR THE MODULATION OF THE CATALYTIC ACTIVITY OF PROTEINQUINASE; A METHOD TO TREAT OR PREVENT AN AFFECTION RELATED TO PROTEINQUINASE
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004113304A1 (en) 2003-05-22 2004-12-29 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
MXPA05012723A (en) 2003-05-30 2006-02-08 Genentech Inc Treatment with anti-vegf antibodies.
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
UA96139C2 (en) 2005-11-08 2011-10-10 Дженентек, Інк. Anti-neuropilin-1 (nrp1) antibody

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010003057A2 (en) * 2008-07-03 2010-01-07 Mayo Foundation For Medical Education And Research Treating cancer
WO2010006232A1 (en) * 2008-07-11 2010-01-14 Genentech, Inc. Methods and compositions for diagnostic use for tumor treatment
WO2011008696A2 (en) * 2009-07-13 2011-01-20 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
WO2011107939A1 (en) * 2010-03-01 2011-09-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of predicting efficacy of an anti-vegfa treatment for solid tumors

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AFFYMETRIX: "GeneChip TM Human Genome U133 Set", INTERNET CITATION, 2001, pages 1 - 2, XP002613737, Retrieved from the Internet <URL:http://www.helmholtz-hzi.de/fileadmin/user_upload/research/Research_P rogramme/Technological_Platforms/Gene_Expression_Analysis/Service/hum angenomeu133.pdf> [retrieved on 20101210] *
BERTUCCI FRANOIS ET AL: "Gene expression profiling of human melanoma cell lines with distinct metastatic potential identifies new progression markers", ANTICANCER RESEARCH, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, vol. 27, no. 5A, 1 September 2007 (2007-09-01), pages 3441 - 3449, XP009154071, ISSN: 0250-7005 *
BOONKITTICHAROEN VIPA ET AL: "Vascular endothelial growth factor a and proliferation marker in prediction of lymph node metastasis in oral and pharyngeal squamous cell carcinoma", ARCHIVES OF OTOLARYNGOLOGY--HEAD & NECK SURGERY,, vol. 134, no. 12, 1 December 2008 (2008-12-01), pages 1305 - 1311, XP009154014, ISSN: 1538-361X *
HOLTZ DAVID O ET AL: "Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer", JOURNAL OF TRANSLATIONAL MEDICINE, BIOMED CENTRAL, LONDON, GB, vol. 6, no. 1, 8 January 2008 (2008-01-08), pages 2, XP021037665, ISSN: 1479-5876 *
LEVINE A M ET AL: "PHASE I TRIAL OF VASCULAR ENDOTHELIAL GROWTH FACTOR-ANTISENSE (VEGF-AS, VEGLIN) IN RELAPSED AND REFRACTORY MALIGNANCIES", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 102, no. 11, 16 November 2003 (2003-11-16), XP009069321, ISSN: 0006-4971 *
PEREZ DOMINGO G ET AL: "Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A", CANCER, AMERICAN CANCER SOCIETY, PHILADELPHIA, PA, US, vol. 115, no. 1, 1 January 2009 (2009-01-01), pages 119 - 127, XP002573186, ISSN: 0008-543X, [retrieved on 20081217], DOI: 10.1002/CNCR.23987 *
SIEGEL ABBY B ET AL: "Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 20 JUN 2008 LNKD- PUBMED:18565886, vol. 26, no. 18, 20 June 2008 (2008-06-20), pages 2992 - 2998, XP002663756, ISSN: 1527-7755 *
STOLLMAN THAMAR H ET AL: "Tumor Accumulation of Radiolabeled Bevacizumab due to Targeting of", CANCER BIOTHERAPY & RADIOPHARMACEUTICALS, MARY ANN LIEBERT, US, vol. 24, no. 2, 1 April 2009 (2009-04-01), pages 195 - 200, XP009154022, ISSN: 1084-9785 *
VAREY A H R ET AL: "VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy", BRITISH JOURNAL OF CANCER, NATURE PUBLISHING GROUP, LONDON, GB, vol. 98, no. 8, 22 April 2008 (2008-04-22), pages 1366 - 1379, XP002552167, ISSN: 0007-0920, [retrieved on 20080318], DOI: 10.1038/SJ.BJC.6604308 *

Also Published As

Publication number Publication date
WO2011153224A2 (en) 2011-12-08

Similar Documents

Publication Publication Date Title
WO2012048099A3 (en) Nanoparticle-loaded cells
WO2014028461A3 (en) Treatment and diagnosis of melanoma
WO2008100805A3 (en) Anti-robo4 antibodies and uses therefor
WO2009108860A3 (en) Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
WO2009126688A8 (en) Novel compositions and methods for the treatment of immune related diseases
EP2323677A4 (en) Micro-rna-based compositions and methods for the diagnosis, prognosis and treatment of multiple myeloma
HK1178074A1 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2012047631A3 (en) Compositions and methods useful for the treatment and diagnosis of inflammatory bowel disease
WO2008120098A3 (en) Peptide prodrugs
WO2011133504A3 (en) Nanozymes, methods of making nanozymes, and methods of using nanozymes
MX347734B (en) S100a4 antibodies and therapeutic uses thereof.
WO2012103810A1 (en) Certain chemical entities, compositions, and methods
IL240560A0 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2014071067A3 (en) Treatment and diagnosis of colon cancer
WO2010101793A3 (en) Methods and compositions for the diagnosis, prognosis and treatment of cancer
WO2012037116A3 (en) Genetic variations associated with common variable immunodeficiency (cvid) and methods of use thereof
WO2012024350A3 (en) Anti-cancer adenoviruses
WO2013052108A3 (en) Methods and compositions for the treatment and diagnosis of ovarian cancer
IN2012DN03404A (en)
WO2012064743A3 (en) Methods for improving heart function
WO2012109567A3 (en) Treatment of angiogenesis disorders
EP2576575A4 (en) Prostaglandin-bisphosphonate conjugate compounds, methods of making same, and uses thereof
WO2011146390A3 (en) Compositions and methods for in vivo imaging
WO2011041701A3 (en) Inplantable contrast agents and methods
WO2011130697A3 (en) Tissue targeting

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11725571

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11725571

Country of ref document: EP

Kind code of ref document: A2